Literature DB >> 7576748

The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.

R R Nordal1, G B Kristensen, J Kaern, A E Stenwig, E O Pettersen, C G Tropé.   

Abstract

To analyze the significance of DNA ploidy in uterine leiomyosarcoma, the traditional clinical and histopathological prognostic variables and DNA ploidy were studied in 70 patients with histologically verified uterine leiomyosarcoma. Evaluable flow cytometric DNA histograms from paraffin-embedded tissue from the tumor were obtained in 58 patients. In univariate analysis tumor diameter, FIGO stage and presence of residual disease after primary surgery were highly significant (p < 0.001) and also DNA ploidy (p = 0.043), age (p = 0.017), and menopause status (p = 0.028) obtained significance. Cellular atypia was almost significant (p = 0.056), while mitotic count, malignancy grade and vessel invasion were not. In Cox's multivariate analysis, FIGO-stage was found to be the most important prognostic factor (p < 0.001), followed by cellular atypia (p = 0.007) and tumor diameter (p = 0.016). DNA ploidy did not obtain significance when categorized as diploid/non-diploid. Patients with tumors with multiple aneuploid cell populations had a very poor prognosis. When categorized as multiple aneuploidy versus all other ploidy groups, DNA ploidy obtained marginal significance in multivariate analysis (p = 0.054). Tumor diameter, stage and cellular atypia are important prognostic parameters in uterine leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576748     DOI: 10.3109/02841869509127189

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

1.  Uterine leiomyosarcoma in asian patients: validation of the revised Federation of gynecology and obstetrics staging system and identification of prognostic classifiers.

Authors:  Pei-Shan Tan; Elisa Koh; Cindy Pang; Whee-Sze Ong; Lynette Ngo; Lay-Tin Soh; Richard Quek; Wen-Yee Chay; Tew-Hong Ho; Sun-Kuie Tay; Sung-Hock Chew; Soo-Kim Lim-Tan; Hs Khoo-Tan; Sheow Lei Lim; Inny Busmanis; Liang Kee Goh; Yin-Nin Chia; Whay-Kuang Chia; Timothy Lim
Journal:  Oncologist       Date:  2012-07-24

2.  Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.

Authors:  Sabrina Croce; Agnès Ducoulombier; Agnès Ribeiro; Tom Lesluyes; Jean-Christophe Noel; Frédéric Amant; Louis Guillou; Eberhard Stoeckle; Mojgan Devouassoux-Shisheboran; Nicolas Penel; Anne Floquet; Laurent Arnould; Frédéric Guyon; Florence Mishellany; Camille Chakiba; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Isabelle Farre; Catherine Genestie; Isabelle Valo; Gaëtan MacGrogan; Frédéric Chibon
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.

Authors:  David B Chapel; Aarti Sharma; Ricardo R Lastra; Livia Maccio; Emma Bragantini; Gian Franco Zannoni; Suzanne George; Bradley J Quade; Carlos Parra-Herran; Marisa R Nucci
Journal:  Mod Pathol       Date:  2022-02-04       Impact factor: 7.842

4.  Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Authors:  Kristelle Lusby; Kari Brewer Savannah; Elizabeth G Demicco; Yiqun Zhang; Markus Ph Ghadimi; Eric D Young; Chiara Colombo; Ryan Lam; Tugce E Dogan; Jason L Hornick; Alexander J Lazar; Kelly K Hunt; Matthew L Anderson; Chad J Creighton; Dina Lev; Raphael E Pollock
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

5.  Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.

Authors:  Klaus Bodner; Barbara Bodner-Adler; Oliver Kimberger; Klaus Czerwenka; Klaus Mayerhofer
Journal:  Wien Klin Wochenschr       Date:  2004-02-28       Impact factor: 1.704

6.  Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.

Authors:  Oliver Zivanovic; Mario M Leitao; Alexia Iasonos; Lindsay M Jacks; Qin Zhou; Nadeem R Abu-Rustum; Robert A Soslow; Margrit M Juretzka; Dennis S Chi; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 7.  Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.

Authors:  Jomjit Chantharasamee; Karlton Wong; Pasathorn Potivongsajarn; Amir Qorbani; Neda Motamed; Sandra Brackert; Joshua Cohen; Bartosz Chmielowski; Anusha Kalbasi; Jianyu Rao; Scott Nelson; Arun Singh
Journal:  Cancer Med       Date:  2022-03-20       Impact factor: 4.711

8.  Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study).

Authors:  Ka-Yu Tse; Richard Wing-Cheuk Wong; Angel Chao; Shir-Hwa Ueng; Lan-Yan Yang; Margaret Cummings; Deborah Smith; Chiung-Ru Lai; Hei-Yu Lau; Ming-Shyen Yen; Annie Nga-Yin Cheung; Charlotte Ka-Lun Leung; Kit-Sheung Chan; Alice Ngot-Htain Chan; Wai-Hon Li; Carmen Ka-Man Choi; Wai-Mei Pong; Hoi-Fong Hui; Judy Ying-Wah Yuk; Hung Yao; Nancy Wah-Fun Yuen; Andreas Obermair; Chyong-Huey Lai; Philip Pun-Ching Ip; Hextan Yuen-Sheung Ngan
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma.

Authors:  Philip Wong; Kathy Han; Jenna Sykes; Charles Catton; Stephane Laframboise; Anthony Fyles; Lee Manchul; Wilfred Levin; Michael Milosevic
Journal:  Radiat Oncol       Date:  2013-05-24       Impact factor: 3.481

10.  Prognostic Value of Microvessel Density in Tumor and Peritumoral Area as Evaluated by CD31 Protein Expression and Argyrophilic Nucleolar Organizer Region Count in Endothelial Cells in Uterine Leiomyosarcoma.

Authors:  Ashot Avdalyan; Igor Bobrov; Vladimir Klimachev; Alexander Lazarev
Journal:  Sarcoma       Date:  2012-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.